Share on StockTwits

United Therapeutics (NASDAQ:UTHR) Director Christopher Causey unloaded 1,500 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The stock was sold at an average price of $91.14, for a total transaction of $136,710.00. Following the completion of the transaction, the director now directly owns 733 shares in the company, valued at approximately $66,806. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

A number of research firms have recently commented on UTHR. Analysts at Wedbush raised their price target on shares of United Therapeutics from $119.00 to $133.00 in a research note on Thursday, July 31st. Separately, analysts at RBC Capital raised their price target on shares of United Therapeutics from $90.00 to $93.00 in a research note on Thursday, July 31st. Finally, analysts at HC Wainwright raised their price target on shares of United Therapeutics from $120.00 to $150.00 in a research note on Wednesday, July 30th. They now have a “buy” rating on the stock. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $102.21.

Shares of United Therapeutics (NASDAQ:UTHR) traded up 2.26% on Friday, hitting $91.79. The stock had a trading volume of 571,332 shares. United Therapeutics has a 1-year low of $70.34 and a 1-year high of $116.65. The stock has a 50-day moving average of $90.90 and a 200-day moving average of $95.98. The company has a market cap of $4.339 billion and a P/E ratio of 17.34.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Tuesday, July 29th. The company reported $2.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.75 by $0.82. The company had revenue of $322.80 million for the quarter, compared to the consensus estimate of $308.04 million. During the same quarter in the previous year, the company posted $1.52 earnings per share. The company’s revenue for the quarter was up 15.0% on a year-over-year basis. On average, analysts predict that United Therapeutics will post $8.55 earnings per share for the current fiscal year.

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.